TD Cowen downgraded Boston Scientific's stock rating from Buy to Hold and set a price target of $46. This analyst action signals a more cautious outlook on the medical device manufacturer, which could lead to short-term selling pressure on the stock.
Investment firm TD Cowen downgraded Boston Scientific's stock rating from Buy to Hold on October 30, 2026, also establishing a new price target of $46. This action reflects a more conservative outlook from a notable financial institution on the medical device manufacturer. For traders, this typically signals potential downward pressure on BSX shares in the short term, as institutional investors may re-evaluate their positions. While not a fundamental change in the company's operations, analyst downgrades can influence market sentiment and investor confidence, making it a key event for those holding or considering trading Boston Scientific stock. The long-term implications depend on whether other analysts follow suit or if the company's fundamentals can quickly re-establish a positive narrative.